Fresenius Medical Care
Fresenius Medical Care, a leading global provider of products and services for individuals with renal diseases, is headquartered in the United States. Founded in 1996, the company has established a strong presence in North America, Europe, and Asia, focusing on dialysis services and the manufacture of dialysis equipment. With a commitment to innovation, Fresenius Medical Care offers a comprehensive range of products, including dialysis machines and consumables, which are distinguished by their advanced technology and patient-centric design. The company is recognised for its significant market position, serving millions of patients worldwide and achieving notable milestones in improving patient outcomes. As a key player in the healthcare industry, Fresenius Medical Care continues to lead in the development of integrated care solutions, enhancing the quality of life for those affected by chronic kidney disease.
DitchCarbon Score
How does Fresenius Medical Care's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Medical Care's score of 80 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Medical Care's reported carbon emissions
In 2024, Fresenius Medical Care reported total carbon emissions of approximately 3,680,800 kg CO2e. This includes Scope 1 emissions of about 360,800 kg CO2e, Scope 2 emissions of approximately 450,600 kg CO2e, and significant Scope 3 emissions totalling around 7,856,500 kg CO2e. The company has set ambitious targets to reduce its direct (Scope 1) and indirect (Scope 2) greenhouse gas emissions by 50% by 2030, using 2020 as the baseline year. This commitment aligns with their broader climate strategy, which includes a net-zero target by 2050, as confirmed by the Science Based Targets initiative (SBTi). In 2023, the company reported total emissions of approximately 3,084,000,000 kg CO2e, with Scope 1 emissions at about 260,800,000 kg CO2e and Scope 2 emissions at approximately 395,800,000 kg CO2e. The Scope 3 emissions for that year were notably high, reaching around 3,084,000,000 kg CO2e, indicating a significant area for improvement. Fresenius Medical Care's emissions data is not cascaded from any parent company, ensuring that their reported figures reflect their own operational impact. The company is committed to transparency and accountability in its climate commitments, aiming to enhance sustainability within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000.0 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000.0 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Medical Care is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
